Company intelligence / Profile preview
Flag Bio, Inc.
East Aurora, New York, United Statesflag.bio ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
As of October 2022, Flag Bio received a $1.98M grant from the Bill & Melinda Gates Foundation to develop new innate immune activation approaches to protect against infectious pathogens in the developing world. The project is focused on creating novel technology platform capabilities and is likely at an early/preclinical stage.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Innate immune activation approaches
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Bill & Melinda Gates Foundation (grant partner)
Beyond the preview
Go deeper on Flag Bio, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Flag Bio, Inc..